transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP

Författare och institution:
R Press (-); Askmark H (-); A Svenningsson (-); Oluf Andersen (Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering); HW Axelsson (-); U Strömberg (-); A Wahlin (-); C Isaksson (-); J-E Johansson (-); Hägglund H (-)
Publicerad i:
Journal of Neurology, Neurosurgery and Psychiatry, 85 ( 6 ) s. 618-624
Artikel, refereegranskad vetenskaplig
Sammanfattning (abstract):
OBJECTIVE: Only 70-80% of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) respond satisfactorily to the established first-line immunomodulatory treatments. Autologous haematopoietic stem cell transplantation (AHSCT) has been performed as a last treatment resort in a few therapy-refractory cases with CIDP. We describe the results of AHSCT in 11 consecutive Swedish patients with therapy-refractory CIDP with a median follow-up time of 28 months. METHOD: Case data were gathered retrospectively for AHSCT treatments in 11 patients with CIDP refractory to the first-line immunomodulatory treatments, intravenous high-dose immunoglobulin, corticosteroids and plasma exchange and to one or more second-line treatments used in 10 of the 11 patients. RESULTS: The median Inflammatory Neuropathy Cause and Treatment (INCAT) score within 1 month prior to AHSCT was 6 and the Rankin score 4. Total INCAT and Rankin scores improved significantly within 2-6 months after AHSCT and continued to do so at last follow-up. The motor action potential amplitudes (CMAP) improved already within 4 months (median) after AHSCT. Three of the 11 patients relapsed during the follow-up period, requiring retransplantation with AHSCT in one. Eight of the 11 patients maintained drug-free remission upon last follow-up. AHSCT was safe but on the short term associated with a risk of cytomegalovirus (CMV) and Epstein-Barr virus reactivation, CMV disease, haemorrhagic cystitis and pancreatitis. CONCLUSIONS: Our results though hampered by the limited number of patients and the lack of a control group suggest AHSCT to be efficacious in therapy-refractory CIDP, with a manageable complication profile. Confirmation of these results is necessary through randomised controlled trials.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Klinisk medicin
CIDP, therapy, stem cell transplantation
Postens nummer:
Posten skapad:
2013-12-23 16:56
Posten ändrad:
2014-06-24 10:24

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007